

SENATE SUBSTITUTE  
FOR  
SENATE BILL NO. 1605  
AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof three new sections relating to 7-hydroxymitragynine.

---

*Be it enacted by the General Assembly of the State of Missouri, as follows:*

Section A. Section 195.017, RSMo, is repealed and three  
2 new sections enacted in lieu thereof, to be known as sections  
3 195.017, 196.1170, and 196.1175, to read as follows:

195.017. 1. The department of health and senior  
2 services shall place a substance in Schedule I if it finds  
3 that the substance:

4 (1) Has high potential for abuse; and

5 (2) Has no accepted medical use in treatment in the  
6 United States or lacks accepted safety for use in treatment  
7 under medical supervision.

8 2. Schedule I:

9 (1) The controlled substances listed in this  
10 subsection are included in Schedule I;

11 (2) Any of the following opiates, including their  
12 isomers, esters, ethers, salts, and salts of isomers,  
13 esters, and ethers, unless specifically excepted, whenever  
14 the existence of these isomers, esters, ethers and salts is  
15 possible within the specific chemical designation:

16 (a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-  
17 phenethyl)-4-piperidinyl)-N-phenylacetamide);

18 (b) Acetylmethadol;

19 (c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
20 phenylacetamide);

21 (d) Acryl fentanyl (- (1-phenethylpiperidin-4-yl) -N-  
22 phenylacrylamide);  
23 (e) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
24 cyclohexylmethyl] benzamide);  
25 (f) Allylprodine;  
26 (g) Alphacetylmethadol (except levoalphacetylmethadol,  
27 also known as levo-alpha-acetylmethadol levothadyl acetate  
28 or LAAM);  
29 (h) Alphameprodine;  
30 (i) Alphamethadol;  
31 (j) Alpha-methylfentanyl (N-1-(alphamethyl-beta-  
32 phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-  
33 phenylethyl)-4 ((N-propanilido) piperidine);  
34 (k) Alpha-methylthiofentanyl (N-(1-methyl-2-(2-  
35 thienyl) ethyl-4-piperidinyl) -N-phenylpropanamide);  
36 (l) Benzethidine;  
37 (m) Betacetylmethadol;  
38 (n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl) -  
39 4-piperidinyl) -N-phenylpropanamide);  
40 (o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-  
41 phenethyl) -3-methyl-4-piperidinyl) -N-phenylpropanamide);  
42 (p) Betameprodine;  
43 (q) Betamethadol;  
44 (r) Betaprodine;  
45 (s) Clonitazene;  
46 (t) Dextromoramide;  
47 (u) Diampromide;  
48 (v) Cyclopropyl fentanyl;  
49 (w) Diethylthiambutene;  
50 (x) Difenoazin;  
51 (y) Dimenoxadol;  
52 (z) Dimepheptanol;  
53 (aa) Dimethylthiambutene;

54 (bb) Dioxaphetyl butyrate;  
55 (cc) Dipipanone;  
56 (dd) Ethylmethylthiambutene;  
57 (ee) Etonitazene;  
58 (ff) Etoperidine;  
59 (gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N-  
60 (1-phenethylpiperidin-4-yl)isobutyramide;  
61 (hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N-  
62 phenylfuran-2-carboxamide;  
63 (ii) Furethidine;  
64 (jj) Hydroxypethidine;  
65 (kk) Ketobemidone;  
66 (ll) Levomoramide;  
67 (mm) Levophenacilmorphan;  
68 (nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4-  
69 piperidyl)-N-phenylpropanamide), its optical and geometric  
70 isomers, salts, and salts of isomers;  
71 (oo) 3-Methylthiofentanyl (N-((3-methyl-1-(2-  
72 thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide);  
73 (pp) Methoxyacetyl fentanyl (2-methoxy-N-(1-  
74 phenethylpiperidin-4-yl)-N-phenylacetamide);  
75 (qq) Morpheridine;  
76 (rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);  
77 (ss) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)  
78 piperazine);  
79 (tt) Noracymethadol;  
80 (uu) Norlevorphanol;  
81 (vv) Normethadone;  
82 (ww) Norpipanone;  
83 (xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1-  
84 phenethylpiperidin-4-yl)acetamide;  
85 (yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin-  
86 yl)propionamide); other name 2-fluorofentanyl;

87 (zz) para-fluorobutyryl fentanyl (N-4-fluorophenyl)-N-  
88 (1-phenethylpiperidin-4-yl)butyramide;  
89 (aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2-  
90 phenethyl)-4-piperidinyl) propanamide;  
91 (bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4-  
92 acetoxypiperidine);  
93 (ccc) Phenadoxone;  
94 (ddd) Phenampromide;  
95 (eee) Phenomorphan;  
96 (fff) Phenoperidine;  
97 (ggg) Piritramide;  
98 (hhh) Proheptazine;  
99 (iii) Properidine;  
100 (jjj) Propiram;  
101 (kkk) Racemoramide;  
102 (lll) Tetrahydrofuranlyl fentanyl (N-(1-  
103 phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-  
104 carboxamide);  
105 (mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4-  
106 piperidinyl)-propanamide;  
107 (nnn) Tilidine;  
108 (ooo) Trimeperidine;  
109 (3) Any of the following opium derivatives, their  
110 salts, isomers and salts of isomers unless specifically  
111 excepted, whenever the existence of these salts, isomers and  
112 salts of isomers is possible within the specific chemical  
113 designation:  
114 (a) Acetorphine;  
115 (b) Acetyldihydrocodeine;  
116 (c) Benzylmorphine;  
117 (d) Codeine methylbromide;  
118 (e) Codeine-N-Oxide;  
119 (f) Cyrenorphine;

120 (g) Desomorphine;  
121 (h) Dihydromorphine;  
122 (i) Drotebanol;  
123 (j) Etorphine (except hydrochloride salt);  
124 (k) Heroin;  
125 (l) Hydromorphenol;  
126 (m) Methyldesorphine;  
127 (n) Methyldihydromorphine;  
128 (o) Morphine methylbromide;  
129 (p) Morphine methylsulfonate;  
130 (q) Morphine-N-Oxide;  
131 (r) Myrophine;  
132 (s) Nicocodeine;  
133 (t) Nicomorphine;  
134 (u) Normorphine;  
135 (v) Pholcodine;  
136 (w) Thebacon;  
137 (4) Any of the following opiate similar synthetic  
138 substances scheduled by the U.S. Drug Enforcement  
139 Administration as substances that share a pharmacological  
140 profile similar to fentanyl, morphine, and other synthetic  
141 opioids, unless specifically excepted or unless listed in  
142 another schedule:  
143 (a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
144 phenylbutyramide);  
145 (b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino)  
146 cyclohexyl]-methyl benzamide).  
147 (5) Any material, compound, mixture or preparation  
148 which contains any quantity of the following hallucinogenic  
149 substances, their salts, isomers and salts of isomers,  
150 unless specifically excepted, whenever the existence of  
151 these salts, isomers, and salts of isomers is possible  
152 within the specific chemical designation:

- 153 (a) Alpha-ethyltryptamine;
- 154 (b) 4-bromo-2,5-dimethoxyamphetamine;
- 155 (c) 4-bromo-2,5-dimethoxyphenethylamine;
- 156 (d) 2,5-dimethoxyamphetamine;
- 157 (e) 2,5-dimethoxy-4-ethylamphetamine;
- 158 (f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 159 (g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine;
- 160 (h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine;
- 161 (i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine;
- 162 (j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine;
- 163 (k) 2-(2,5-Dimethoxyphenyl) ethanamine;
- 164 (l) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine;
- 165 (m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine;
- 166 (n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine;
- 167 (o) 2-(4-Isopropylthio)-2,5-dimethoxyphenyl)
- 168 ethanamine;
- 169 (p) 4-methoxyamphetamine;
- 170 (q) 5-methoxy-3,4-methylenedioxyamphetamine;
- 171 (r) 4-methyl-2,5-dimethoxyamphetamine;
- 172 (s) 3,4-methylenedioxyamphetamine;
- 173 (t) 3,4-methylenedioxymethamphetamine;
- 174 (u) 3,4-methylenedioxy-N-ethylamphetamine;
- 175 (v) N-hydroxy-3,4-methylenedioxyamphetamine;
- 176 (w) 3,4,5-trimethoxyamphetamine;
- 177 (x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine;
- 178 (y) Alpha-methyltryptamine;
- 179 (z) Bufotenine;
- 180 (aa) Diethyltryptamine;
- 181 (bb) Dimethyltryptamine;
- 182 (cc) 5-methoxy-N,N-diisopropyltryptamine;
- 183 (dd) Ibogaine;
- 184 (ee) Lysergic acid diethylamide;
- 185 (ff) Marijuana or marihuana, except industrial hemp;

186 (gg) Mescaline;  
187 (hh) Parahexyl;  
188 (ii) Peyote, to include all parts of the plant  
189 presently classified botanically as *Lophophora williamsii*  
190 Lemaire, whether growing or not; the seeds thereof; any  
191 extract from any part of such plant; and every compound,  
192 manufacture, salt, derivative, mixture or preparation of the  
193 plant, its seed or extracts;  
194 (jj) N-ethyl-3-piperidyl benzilate;  
195 (kk) N-methyl-3-piperidyl benzilate;  
196 (ll) Psilocybin;  
197 (mm) Psilocyn;  
198 (nn) Tetrahydrocannabinols naturally contained in a  
199 plant of the genus *Cannabis* (*cannabis* plant), except  
200 industrial hemp, as well as synthetic equivalents of the  
201 substances contained in the *cannabis* plant, or in the  
202 resinous extractives of such plant, or synthetic substances,  
203 derivatives and their isomers, or both, with similar  
204 chemical structure and pharmacological activity to those  
205 substances contained in the plant, such as the following:  
206 a. 1 cis or trans tetrahydrocannabinol and their  
207 optical isomers;  
208 b. 6 cis or trans tetrahydrocannabinol and their  
209 optical isomers;  
210 c. 3,4 cis or trans tetrahydrocannabinol and their  
211 optical isomers;  
212 d. Any compounds of these structures, regardless of  
213 numerical designation of atomic positions covered;  
214 (oo) Ethylamine analog of phencyclidine;  
215 (pp) Pyrrolidine analog of phencyclidine;  
216 (qq) Thiophene analog of phencyclidine;  
217 (rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;  
218 (ss) *Salvia divinorum*;

219 (tt) Salvinorin A;  
220 (uu) Synthetic cannabinoids:  
221 a. Any compound structurally derived from 3-(1-  
222 naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by  
223 substitution at the nitrogen atom of the indole ring by  
224 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
225 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-  
226 morpholinyl)ethyl group, whether or not further substituted  
227 in the indole ring to any extent, whether or not substituted  
228 in the naphthyl ring to any extent. Including, but not  
229 limited to:  
230 (i) AM2201, or 1-(5-fluoropentyl)-3-(1-  
231 naphthoyl)indole;  
232 (ii) JWH-007, or 1-pentyl-2-methyl-3-(1-  
233 naphthoyl)indole;  
234 (iii) JWH-015, or 1-propyl-2-methyl-3-(1-  
235 naphthoyl)indole;  
236 (iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;  
237 (v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;  
238 (vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;  
239 (vii) JWH-081, or 1-pentyl-3-(4-methoxy-1-  
240 naphthoyl)indole;  
241 (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-  
242 naphthoyl)indole;  
243 (ix) JWH-122, or 1-pentyl-3-(4-methyl-1-  
244 naphthoyl)indole;  
245 (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-  
246 naphthoyl)indole;  
247 (xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-  
248 naphthoyl)indole;  
249 (xii) JWH-210, or 1-pentyl-3-(4-ethyl-1-  
250 naphthoyl)indole;

251 (xiii) JWH-398, or 1-pentyl-3-(4-chloro-1-  
252 naphthoyl)indole;

253 b. Any compound structurally derived from 3-(1-  
254 naphthoyl)pyrrole by substitution at the nitrogen atom of  
255 the pyrrole ring by alkyl, haloalkyl, alkenyl,  
256 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
257 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
258 or not further substituted in the pyrrole ring to any  
259 extent, whether or not substituted in the naphthyl ring to  
260 any extent;

261 c. Any compound structurally derived from 1-(1-  
262 naphthylmethyl)indene by substitution at the 3-position of  
263 the indene ring by alkyl, haloalkyl, alkenyl,  
264 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
265 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
266 or not further substituted in the indene ring to any extent,  
267 whether or not substituted in the naphthyl ring to any  
268 extent;

269 d. Any compound structurally derived from 3-  
270 phenylacetylindole by substitution at the nitrogen atom of  
271 the indole ring with alkyl, haloalkyl, alkenyl,  
272 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
273 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
274 or not further substituted in the indole ring to any extent,  
275 whether or not substituted in the phenyl ring to any  
276 extent. Including, but not limited to:

277 (i) JWH-201, or 1-pentyl-3-(4-  
278 methoxyphenylacetyl)indole;

279 (ii) JWH-203, or 1-pentyl-3-(2-  
280 chlorophenylacetyl)indole;

281 (iii) JWH-250, or 1-pentyl-3-(2-  
282 methoxyphenylacetyl)indole;

283 (iv) JWH-251, or 1-pentyl-3-(2-  
284 methylphenylacetyl)indole;  
285 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-  
286 methoxyphenylacetyl)indole;  
287 e. Any compound structurally derived from 2-(3-  
288 hydroxycyclohexyl)phenol by substitution at the 5-position  
289 of the phenolic ring by alkyl, haloalkyl, alkenyl,  
290 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
291 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
292 or not substituted in the cyclohexyl ring to any extent.  
293 Including, but not limited to CP 47, 497 and homologues, or  
294 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-  
295 yl)phenol, where side chain n=5, and homologues where side  
296 chain n=4,6, or 7;  
297 f. Any compound containing a 3-(benzoyl)indole  
298 structure with substitution at the nitrogen atom of the  
299 indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
300 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-  
301 morpholinyl)ethyl group, whether or not further substituted  
302 in the indole ring to any extent and whether or not  
303 substituted in the phenyl ring to any extent. Including,  
304 but not limited to:  
305 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-  
306 iodobenzoyl)indole;  
307 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-  
308 19 and RCS-4);  
309 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-  
310 methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-  
311 octahydrophenanthridin-1-yl] acetate;  
312 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-  
313 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
314 tetrahydrobenzo[c]chromen-1-ol;

315 i. HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-  
316 6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
317 tetrahydrobenzo[c]chromen-1-ol;

318 j. Dimethylheptylpyran, or DMHP;

319 (6) Any material, compound, mixture or preparation  
320 containing any quantity of the following substances having a  
321 depressant effect on the central nervous system, including  
322 their salts, isomers and salts of isomers whenever the  
323 existence of these salts, isomers and salts of isomers is  
324 possible within the specific chemical designation:

325 (a) Gamma-hydroxybutyric acid;

326 (b) Mecloqualone;

327 (c) Methaqualone;

328 (7) Any material, compound, mixture or preparation  
329 containing any quantity of the following substances having a  
330 stimulant effect on the central nervous system, including  
331 their salts, isomers and salts of isomers:

332 (a) Aminorex;

333 (b) N-benzylpiperazine;

334 (c) Cathinone;

335 (d) Fenethylamine;

336 (e) 3-Fluoromethcathinone;

337 (f) 4-Fluoromethcathinone;

338 (g) Mephedrone, or 4-methylmethcathinone;

339 (h) Methcathinone;

340 (i) 4-methoxymethcathinone;

341 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-  
342 methyl-5-phenyl-2-oxazolamine);

343 (k) Methylenedioxypropylamphetamine, MDPV, or 1-(1,3-  
344 Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;

345 (l) Methylone, or 3,4-Methylenedioxypropylamphetamine;

346 (m) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP;

347 (n) N-ethylamphetamine;

348 (o) N,N-dimethylamphetamine;

349 (p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-  
350 22; QUPIC);

351 (q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-  
352 carboxylate (5-fluoro-PB-22; 5F-PB-22);

353 (r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-  
354 fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);

355 (s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-  
356 1H-indazole-3-carboxamide (ADB-PINACA);

357 (8) A temporary listing of substances subject to  
358 emergency scheduling under federal law shall include any  
359 material, compound, mixture or preparation which contains  
360 any quantity of the following substances:

361 (a) (1-pentyl-1H-indol-3-yl) (2,2,3,3-  
362 tetramethylcyclopropyl)methanone, its optical, positional,  
363 and geometric isomers, salts, and salts of isomers;

364 (b) [1-(5-fluoro-pentyl)-1H-indol-3-yl] (2,2,3,3-  
365 tetramethylcyclopropyl)methanone, its optical, positional,  
366 and geometric isomers, salts, and salts of isomers;

367 (c) N-(1-adamantyl)-1-pentyl-1H-indazole-3-  
368 carboxamide, its optical, positional, and geometric isomers,  
369 salts, and salts of isomers;

370 (d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
371 methoxybenzyl)ethanamine, its optical, positional, and  
372 geometric isomers, salts, and salts of isomers;

373 (e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
374 methoxybenzyl)ethanamine, its optical, positional, and  
375 geometric isomers, salts, and salts of isomers;

376 (f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
377 methoxybenzyl)ethanamine, its optical, positional, and  
378 geometric isomers, salts, and salts of isomers;

379 (g) 4-methyl-N-ethylcathinone, its optical,  
380 positional, and geometric isomers, salts, and salts of  
381 isomers;

382 (h) 4-methyl-alpha-pyrrolidinopropiophenone, its  
383 optical, positional, and geometric isomers, salts, and salts  
384 of isomers;

385 (i) Alpha-pyrrolidinopentiophenone, its optical,  
386 positional, and geometric isomers, salts, and salts of  
387 isomers;

388 (j) Butylone, its optical, positional, and geometric  
389 isomers, salts, and salts of isomers;

390 (k) Pentedrone, its optical, positional, and geometric  
391 isomers, salts, and salts of isomers;

392 (l) Pentylone, its optical, positional, and geometric  
393 isomers, salts, and salts of isomers;

394 (m) Naphyrone, its optical, positional, and geometric  
395 isomers, salts, and salts of isomers;

396 (n) Alpha-pyrrolidinobutiophenone, its optical,  
397 positional, and geometric isomers, salts, and salts of  
398 isomers;

399 (o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-  
400 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,  
401 positional, and geometric isomers, salts, and salts of  
402 isomers;

403 (p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-  
404 indazole-3-carboxamide, its optical, positional, and  
405 geometric isomers, salts, and salts of isomers;

406 (q) [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1-  
407 yl)methanone, its optical, positional, and geometric  
408 isomers, salts, and salts of isomers;

409 (r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-  
410 4-yl]-N-phenylpropionamide, its isomers, esters, ethers,  
411 salts, and salts of isomers, esters, and ethers;

412 (s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,  
413 its optical, positional, and geometric isomers, salts, and  
414 salts of isomers;

415 (t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
416 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,  
417 positional, and geometric isomers, salts, and salts of  
418 isomers;

419 (u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
420 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
421 and geometric isomers, salts, and salts of isomers;

422 (v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
423 carboxamido)-3-methylbutanoate, its optical, positional, and  
424 geometric isomers, salts, and salts of isomers;

425 (w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-  
426 3-carboxamide, its optical, positional, and geometric  
427 isomers, salts, and salts of isomers;

428 (x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-  
429 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,  
430 positional, and geometric isomers, salts, and salts of  
431 isomers;

432 (y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
433 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
434 and geometric isomers, salts, and salts of isomers;

435 (z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-  
436 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
437 and geometric isomers, salts, and salts of isomers;

438 (aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-  
439 yl)propionamide, its isomers, esters, ethers, salts, and  
440 salts of isomers, esters, and ethers;

441 (bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-  
442 carboxamido)-3-methylbutanoate, its optical, positional, and  
443 geometric isomers, salts, and salts of isomers;

444 (cc) N-(1-phenethylpiperidin-4-yl)-N-  
445 phenylcyclopropanecarboxamide, its isomers, esters, ethers,  
446 salts, and salts of isomers, esters, and ethers;

447 (dd) N-(1-phenethylpiperidin-4-yl)-N-  
448 phenylpentanamide, its isomers, esters, ethers, salts, and  
449 salts of isomers, esters, and ethers;

450 (ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-  
451 yl)butyramide, its isomers, esters, ethers, salts, and salts  
452 of isomers, esters, and ethers;

453 (ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-  
454 yl)butyramide, its isomers, esters, ethers, salts, and salts  
455 of isomers, esters, and ethers;

456 (gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-  
457 yl)isobutyramide, its isomers, esters, ethers, salts, and  
458 salts of isomers, esters, and ethers;

459 (hh) N-(1-phenethylpiperidin-4-yl)-N-  
460 phenylisobutyramide, its isomers, esters, ethers, salts, and  
461 salts of isomers, esters, and ethers;

462 (ii) N-(1-phenethylpiperidin-4-yl)-N-  
463 phenylcyclopentanecarboxamide, its isomers, esters, ethers,  
464 salts, and salts of isomers, esters, and ethers;

465 (jj) Fentanyl-related substances, their isomers,  
466 esters, ethers, salts, and salts of isomers, esters, and  
467 ethers. Fentanyl-related substance shall mean any substance  
468 not otherwise listed under another Drug Enforcement  
469 Administration Controlled Substance Code Number, and for  
470 which no exemption or approval is in effect under section  
471 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.  
472 Section 355, that is structurally related to fentanyl by one  
473 or more of the following modifications:

474 a. Replacement of the phenyl portion of the phenethyl  
475 group by any monocycle, whether or not further substituted  
476 in or on the monocycle;

477           b. Substitution in or on the phenethyl group with  
478 alkyl, alkenyl, alkoxy, hydroxy, halo, haloalkyl, amino or  
479 nitro groups;

480           c. Substitution in or on the piperidine ring with  
481 alkyl, alkenyl, alkoxy, ester, ether, hydroxy, amino or  
482 nitro groups;

483           d. Replacement of the aniline ring with any aromatic  
484 monocycle, whether or not further substituted in or on the  
485 aromatic monocycle; or

486           e. Replacement of the N-propionyl group by another  
487 acyl group;

488           (kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-  
489 carboxylate, its optical, positional, and geometric isomers,  
490 salts, and salts of isomers (NM2201; CBL2201);

491           (ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-  
492 fluoropentyl)-1H-indazole-3-carboxamide, its optical,  
493 positional, and geometric isomers, salts, and salts of  
494 isomers (5F-AB-PINACA);

495           (mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-  
496 indazole-3-carboxamide, its optical, positional, and  
497 geometric isomers, salts, and salts of isomers (4-CN-CUMYL-  
498 BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-  
499 4CN-BINACA; SGT-78);

500           (nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
501 carboxamido)-3-methylbutanoate, its optical, positional, and  
502 geometric isomers, salts, and salts of isomers (MMB-CHMICA,  
503 AMB-CHMICA);

504           (oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
505 pyrrolo[2,3-b]pyridine-3-carboxamide, its optical,  
506 positional, and geometric isomers, salts, and salts of  
507 isomers (5F-CUMYL-P7AICA);

508 (pp) N-ethylpentylone, its optical, positional, and  
509 geometric isomers, salts, and salts of isomers (ephylone, 1-  
510 (1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one;  
511 (qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
512 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
513 and geometric isomers, salts, and salts of isomers (trivial  
514 name: 5F-EDMB-PINACA);  
515 (rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-  
516 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
517 and geometric isomers, salts, and salts of isomers (trivial  
518 name: 5F-MDMB-PICA);  
519 (ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-  
520 3-carboxamide, its optical, positional, and geometric  
521 isomers, salts, and salts of isomers (trivial names: FUB-  
522 AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL));  
523 (tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
524 indazole-3-carboxamide, its optical, positional, and  
525 geometric isomers, salts, and salts of isomers (trivial  
526 names: 5F-CUMYL-PINACA; SGT-25);  
527 (uu) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-  
528 tetramethylcyclopropyl) methanone, its optical, positional,  
529 and geometric isomers, salts, and salts of isomers (trivial  
530 name: FUB-144);  
531 (vv) N-ethylhexedrone, its optical, positional, and  
532 geometric isomers, salts, and salts of isomers (Other name:  
533 2-(ethylamino)-1-phenylhexan-1-one);  
534 (ww) alpha-pyrrolidinohexanophenone, its optical,  
535 positional, and geometric isomers, salts, and salts of  
536 isomers (Other names:  $\alpha$ -PHP; alpha-pyrrolidinohexiophenone;  
537 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);  
538 (xx) 4-methyl-alpha-ethylaminopentiophenone, its  
539 optical, positional, and geometric isomers, salts, and salts

540 of isomers; (Other names: 4-MEAP; 2-(ethylamino)-1-(4-  
541 methylphenyl)pentan-1-one);  
542 (yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its  
543 optical, positional, and geometric isomers, salts, and salts  
544 of isomers (Other names: MPHP; 4'-methyl-alpha-  
545 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-  
546 yl)hexan-1-one);  
547 (zz) alpha-pyrrolidinoheptaphenone, its optical,  
548 positional, and geometric isomers, salts, and salts of  
549 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-  
550 yl)heptan-1-one);  
551 (aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its  
552 optical, positional, and geometric isomers, salts, and salts  
553 of isomers (Other names: 4-chloro- $\alpha$ -PVP; 4'-chloro-alpha-  
554 pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-  
555 yl)pentan-1-one);  
556 (9) Khat, to include all parts of the plant presently  
557 classified botanically as catha edulis, whether growing or  
558 not; the seeds thereof; any extract from any part of such  
559 plant; and every compound, manufacture, salt, derivative,  
560 mixture, or preparation of the plant, its seed or extracts;  
561 (10) 7-Hydroxymitragynine (methyl (E)-2-  
562 [(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-  
563 hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-  
564 enoate) concentrated at a level above one thousand parts per  
565 million on a dry-weight basis.  
566 3. The department of health and senior services shall  
567 place a substance in Schedule II if it finds that:  
568 (1) The substance has high potential for abuse;  
569 (2) The substance has currently accepted medical use  
570 in treatment in the United States, or currently accepted  
571 medical use with severe restrictions; and

572           (3) The abuse of the substance may lead to severe  
573           psychic or physical dependence.

574           4. The controlled substances listed in this subsection  
575           are included in Schedule II:

576           (1) Any of the following substances whether produced  
577           directly or indirectly by extraction from substances of  
578           vegetable origin, or independently by means of chemical  
579           synthesis, or by combination of extraction and chemical  
580           synthesis:

581           (a) Opium and opiate; and any salt, compound,  
582           derivative or preparation of opium or opiate, excluding  
583           apomorphine, thebaine-derived butorphanol, dextrorphan,  
584           nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone,  
585           and their respective salts, but including the following:

- 586           a. Raw opium;
- 587           b. Opium extracts;
- 588           c. Opium fluid;
- 589           d. Powdered opium;
- 590           e. Granulated opium;
- 591           f. Tincture of opium;
- 592           g. Codeine;
- 593           h. Dihydroetorphine;
- 594           i. Ethylmorphine;
- 595           j. Etorphine hydrochloride;
- 596           k. Hydrocodone;
- 597           l. Hydromorphone;
- 598           m. Metopon;
- 599           n. Morphine;
- 600           o. Oripavine;
- 601           p. Oxycodone;
- 602           q. Oxymorphone;
- 603           r. Thebaine;

604 (b) Any salt, compound, derivative, or preparation  
605 thereof which is chemically equivalent or identical with any  
606 of the substances referred to in this subdivision, but not  
607 including the isoquinoline alkaloids of opium;

608 (c) Opium poppy and poppy straw;

609 (d) Coca leaves and any salt, compound, derivative, or  
610 preparation of coca leaves, and any salt, compound,  
611 derivative, or preparation thereof which is chemically  
612 equivalent or identical with any of these substances, but  
613 not including the following:

614 a. Decocainized coca leaves or extractions of coca  
615 leaves, which extractions do not contain cocaine or  
616 ecgonine; or

617 b. Ioflupane;

618 (e) Concentrate of poppy straw (the crude extract of  
619 poppy straw in either liquid, solid or powder form which  
620 contains the phenanthrene alkaloids of the opium poppy);

621 (2) Any of the following opiates, including their  
622 isomers, esters, ethers, salts, and salts of isomers,  
623 whenever the existence of these isomers, esters, ethers, and  
624 salts is possible within the specific chemical designation,  
625 dextrorphan and levopropoxyphene excepted:

626 (a) Alfentanil;

627 (b) Alphaprodine;

628 (c) Anileridine;

629 (d) Bezitramide;

630 (e) Bulk dextropropoxyphene;

631 (f) Carfentanil;

632 (g) Dihydrocodeine;

633 (h) Diphenoxylate;

634 (i) Fentanyl;

635 (j) Isomethadone;

636 (k) Levo-alphaacetylmethadol;

- 637 (l) Levomethorphan;
- 638 (m) Levorphanol;
- 639 (n) Metazocine;
- 640 (o) Methadone;
- 641 (p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,  
642 4-diphenylbutane;
- 643 (q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-  
644 diphenylpropane-carboxylic acid;
- 645 (r) Pethidine (meperidine);
- 646 (s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-  
647 phenylpiperidine;
- 648 (t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-  
649 4-carboxylate;
- 650 (u) Pethidine-Intermediate-C, 1-methyl-4-  
651 phenylpiperidine-4-carboxylic acid;
- 652 (v) Phenazocine;
- 653 (w) Piminodine;
- 654 (x) Racemethorphan;
- 655 (y) Racemorphan;
- 656 (z) Remifentanil;
- 657 (aa) Sufentanil;
- 658 (bb) Tapentadol;
- 659 (cc) Thiafentanil;
- 660 (3) Any material, compound, mixture, or preparation  
661 which contains any quantity of the following substances  
662 having a stimulant effect on the central nervous system:
- 663 (a) Amphetamine, its salts, optical isomers, and salts  
664 of its optical isomers;
- 665 (b) Lisdexamfetamine, its salts, isomers, and salts of  
666 its isomers;
- 667 (c) Methamphetamine, its salts, isomers, and salts of  
668 its isomers;
- 669 (d) Phenmetrazine and its salts;

670 (e) Methylphenidate;

671 (4) Any material, compound, mixture, or preparation  
672 which contains any quantity of the following substances  
673 having a depressant effect on the central nervous system,  
674 including its salts, isomers, and salts of isomers whenever  
675 the existence of those salts, isomers, and salts of isomers  
676 is possible within the specific chemical designation:

677 (a) Amobarbital;

678 (b) Glutethimide;

679 (c) Pentobarbital;

680 (d) Phencyclidine;

681 (e) Secobarbital;

682 (5) Hallucinogenic substances:

683 (a) Any material or compound which contains any  
684 quantity of nabilone;

685 (b) Dronabinol [(-)- $\Delta$ -9-trans tetrahydrocannabinol] in  
686 an oral solution in a drug product approved for marketing by  
687 the U.S. Food and Drug Administration;

688 (6) Any material, compound, mixture, or preparation  
689 which contains any quantity of the following substances:

690 (a) Immediate precursor to amphetamine and  
691 methamphetamine: Phenylacetone;

692 (b) Immediate precursors to phencyclidine (PCP):

693 a. 1-phenylcyclohexylamine;

694 b. 1-piperidinocyclohexanecarbonitrile (PCC);

695 (c) Immediate precursor to fentanyl: 4-anilino-N-  
696 phenethyl-4-piperidine (ANPP);

697 (7) Any material, compound, mixture, or preparation  
698 which contains any quantity of the following alkyl nitrites:

699 (a) Amyl nitrite;

700 (b) Butyl nitrite.

701 5. The department of health and senior services shall  
702 place a substance in Schedule III if it finds that:

703 (1) The substance has a potential for abuse less than  
704 the substances listed in Schedules I and II;

705 (2) The substance has currently accepted medical use  
706 in treatment in the United States; and

707 (3) Abuse of the substance may lead to moderate or low  
708 physical dependence or high psychological dependence.

709 6. The controlled substances listed in this subsection  
710 are included in Schedule III:

711 (1) Any material, compound, mixture, or preparation  
712 which contains any quantity of the following substances  
713 having a potential for abuse associated with a stimulant  
714 effect on the central nervous system:

- 715 (a) Benzphetamine;
- 716 (b) Chlorphentermine;
- 717 (c) Clortermine;
- 718 (d) Phendimetrazine;

719 (2) Any material, compound, mixture or preparation  
720 which contains any quantity or salt of the following  
721 substances or salts having a depressant effect on the  
722 central nervous system:

723 (a) Any material, compound, mixture or preparation  
724 which contains any quantity or salt of the following  
725 substances combined with one or more active medicinal  
726 ingredients:

- 727 a. Amobarbital;
- 728 b. Secobarbital;
- 729 c. Pentobarbital;

730 (b) Any suppository dosage form containing any  
731 quantity or salt of the following:

- 732 a. Amobarbital;
- 733 b. Secobarbital;
- 734 c. Pentobarbital;

735 (c) Any substance which contains any quantity of a  
736 derivative of barbituric acid or its salt;

737 (d) Chlorhexadol;

738 (e) Embutramide;

739 (f) Gamma hydroxybutyric acid and its salts, isomers,  
740 and salts of isomers contained in a drug product for which  
741 an application has been approved under Section 505 of the  
742 federal Food, Drug, and Cosmetic Act;

743 (g) Ketamine, its salts, isomers, and salts of isomers;

744 (h) Lysergic acid;

745 (i) Lysergic acid amide;

746 (j) Methyprylon;

747 (k) Perampanel, and its salts, isomers, and salts of  
748 isomers;

749 (l) Sulfondiethylmethane;

750 (m) Sulfonethylmethane;

751 (n) Sulfonmethane;

752 (o) Tiletamine and zolazepam or any salt thereof;

753 (3) Nalorphine;

754 (4) Any material, compound, mixture, or preparation  
755 containing limited quantities of any of the following  
756 narcotic drugs or their salts:

757 (a) Not more than 1.8 grams of codeine per one hundred  
758 milliliters or not more than ninety milligrams per dosage  
759 unit, with an equal or greater quantity of an isoquinoline  
760 alkaloid of opium;

761 (b) Not more than 1.8 grams of codeine per one hundred  
762 milliliters or not more than ninety milligrams per dosage  
763 unit with one or more active, nonnarcotic ingredients in  
764 recognized therapeutic amounts;

765 (c) Not more than 1.8 grams of dihydrocodeine per one  
766 hundred milliliters or not more than ninety milligrams per

767 dosage unit, with one or more active, nonnarcotic  
768 ingredients in recognized therapeutic amounts;

769 (d) Not more than three hundred milligrams of  
770 ethylmorphine per one hundred milliliters or not more than  
771 fifteen milligrams per dosage unit, with one or more active,  
772 nonnarcotic ingredients in recognized therapeutic amounts;

773 (e) Not more than five hundred milligrams of opium per  
774 one hundred milliliters or per one hundred grams or not more  
775 than twenty-five milligrams per dosage unit, with one or  
776 more active nonnarcotic ingredients in recognized  
777 therapeutic amounts;

778 (f) Not more than fifty milligrams of morphine per one  
779 hundred milliliters or per one hundred grams, with one or  
780 more active, nonnarcotic ingredients in recognized  
781 therapeutic amounts;

782 (5) Any material, compound, mixture, or preparation  
783 containing any of the following narcotic drugs or their  
784 salts: Buprenorphine;

785 (6) Anabolic steroids. Any drug or hormonal  
786 substance, chemically and pharmacologically related to  
787 testosterone (other than estrogens, progestins,  
788 corticosteroids, and dehydroepiandrosterone) that promotes  
789 muscle growth, except an anabolic steroid which is expressly  
790 intended for administration through implants to cattle or  
791 other nonhuman species and which has been approved by the  
792 Secretary of Health and Human Services for that  
793 administration. If any person prescribes, dispenses, or  
794 distributes such steroid for human use, such person shall be  
795 considered to have prescribed, dispensed, or distributed an  
796 anabolic steroid within the meaning of this subdivision.  
797 Unless specifically excepted or unless listed in another  
798 schedule, any material, compound, mixture or preparation

799 containing any quantity of the following substances,  
800 including its salts, esters and ethers:

- 801 (a)  $3\beta,17\beta$ -dihydroxy- $5\alpha$ -androstane;
- 802 (b)  $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androstane;
- 803 (c)  $5\alpha$ -androstan-3,17-dione;
- 804 (d) 1-androstenediol ( $3\beta,17\beta$ -dihydroxy- $5\alpha$ -androst-1-  
805 ene);
- 806 (e) 1-androstenediol ( $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androst-1-  
807 ene);
- 808 (f) 4-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-4-ene);
- 809 (g) 5-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-5-ene);
- 810 (h) 1-androstenedione ([ $5\alpha$ ]-androst-1-en-3,17-dione);
- 811 (i) 4-androstenedione (androst-4-en-3,17-dione);
- 812 (j) 5-androstenedione (androst-5-en-3,17-dione);
- 813 (k) Bolasterone ( $7\alpha,17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-  
814 en-3-one);
- 815 (l) Boldenone ( $17\beta$ -hydroxyandrost-1,4,-diene-3-one);
- 816 (m) Boldione;
- 817 (n) Calusterone ( $7\beta,17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-  
818 en-3-one);
- 819 (o) Clostebol (4-chloro- $17\beta$ -hydroxyandrost-4-en-3-one);
- 820 (p) Dehydrochloromethyltestosterone (4-chloro- $17\beta$ -  
821 hydroxy- $17\alpha$ -methyl-androst-1,4-dien-3-one);
- 822 (q) Desoxymethyltestosterone;
- 823 (r) 4-dihydrotestosterone ( $17\beta$ -hydroxy-androstan-3-  
824 one);
- 825 (s) Drostanolone ( $17\beta$ -hydroxy- $2\alpha$ -methyl- $5\alpha$ -androstan-3-  
826 one);
- 827 (t) Ethylestrenol ( $17\alpha$ -ethyl- $17\beta$ -hydroxyestr-4-ene);
- 828 (u) Fluoxymesterone (9-fluoro- $17\alpha$ -methyl- $11\beta,17\beta$ -  
829 dihydroxyandrost-4-en-3-one);
- 830 (v) Formebolone (2-formyl- $17\alpha$ -methyl- $11\alpha,17\beta$ -  
831 dihydroxyandrost-1,4-dien-3-one);

832 (w) Furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostano[2,3-c]-  
833 furazan);  
834 (x) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;  
835 (y) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-  
836 en-3-one);  
837 (z) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-  
838 4-en-3-one);  
839 (aa) Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androstan-  
840 3-one);  
841 (bb) Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-  
842 androstan-3-one);  
843 (cc) Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-  
844 dien-3-one);  
845 (dd) Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-  
846 ene);  
847 (ee) Methasterone (2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androstan-17 $\beta$ -ol-  
848 3-one);  
849 (ff) Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-  
850 3-one);  
851 (gg) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;  
852 (hh) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;  
853 (ii) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene;  
854 (jj) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-  
855 hydroxy-17 $\beta$ -hydroxyestr-4-en-3-one);  
856 (kk) Methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-  
857 4,9(10)-dien-3-one);  
858 (ll) Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-  
859 4,9,11-trien-3-one);  
860 (mm) Methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-  
861 4-en-3-one);  
862 (nn) Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-  
863 3-one);

864 (oo) 17 $\alpha$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-  
865 17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-one) (a.k.a. '17- $\alpha$ -methyl-1-  
866 testosterone');  
867 (pp) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);  
868 (qq) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-  
869 ene);  
870 (rr) 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-  
871 ene);  
872 (ss) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-  
873 diene-3,17-dione);  
874 (tt) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-  
875 ene);  
876 (uu) 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-  
877 ene);  
878 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);  
879 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
880 (xx) Norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-  
881 3-one);  
882 (yy) Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-  
883 one);  
884 (zz) Norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-  
885 one);  
886 (aaa) Normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-  
887 en-3-one);  
888 (bbb) Oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-  
889 androstan-3-one);  
890 (ccc) Oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-  
891 4-en-3-one);  
892 (ddd) metholone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -  
893 hydroxy-[5 $\alpha$ ]-androstan-3-one);  
894 (eee) Prostanazol (17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one-  
895 c]pyrazole);

896 (fff) Stanolone ( $\Delta$ 1-dihydrotestosterone (a.k.a. 1-  
897 testosterone) ( $17\beta$ -hydroxy- $5\alpha$ -androst-1-en-3-one));  
898 (ggg) Stanozolol ( $17\alpha$ -methyl- $17\beta$ -hydroxy-[ $5\alpha$ ]-androst-  
899 2-eno[3,2-c]-pyrazole);  
900 (hhh) Stenbolone ( $17\beta$ -hydroxy-2-methyl-[ $5\alpha$ ]-androst-1-  
901 en-3-one);  
902 (iii) Testolactone (13-hydroxy-3-oxo-13,17-  
903 secoandrosta-1,4-dien-17-oic acid lactone);  
904 (jjj) Testosterone ( $17\beta$ -hydroxyandrost-4-en-3-one);  
905 (kkk) Tetrahydrogestrinone (13 $\beta$ ,17 $\alpha$ -diethyl- $17\beta$ -  
906 hydroxygon-4,9,11-trien-3-one);  
907 (lll) Trenbolone ( $17\beta$ -hydroxyestr-4,9,11-trien-3-one);  
908 (mmm) Any salt, ester, or ether of a drug or substance  
909 described or listed in this subdivision, except an anabolic  
910 steroid which is expressly intended for administration  
911 through implants to cattle or other nonhuman species and  
912 which has been approved by the Secretary of Health and Human  
913 Services for that administration;  
914 (7) Dronabinol (synthetic) in sesame oil and  
915 encapsulated in a soft gelatin capsule in a United States  
916 Food and Drug Administration approved drug product;  
917 (8) The department of health and senior services may  
918 except by rule any compound, mixture, or preparation  
919 containing any stimulant or depressant substance listed in  
920 subdivisions (1) and (2) of this subsection from the  
921 application of all or any part of sections 195.010 to  
922 195.320 if the compound, mixture, or preparation contains  
923 one or more active medicinal ingredients not having a  
924 stimulant or depressant effect on the central nervous  
925 system, and if the admixtures are included therein in  
926 combinations, quantity, proportion, or concentration that  
927 vitiate the potential for abuse of the substances which have

928 a stimulant or depressant effect on the central nervous  
929 system.

930 7. The department of health and senior services shall  
931 place a substance in Schedule IV if it finds that:

932 (1) The substance has a low potential for abuse  
933 relative to substances in Schedule III;

934 (2) The substance has currently accepted medical use  
935 in treatment in the United States; and

936 (3) Abuse of the substance may lead to limited  
937 physical dependence or psychological dependence relative to  
938 the substances in Schedule III.

939 8. The controlled substances listed in this subsection  
940 are included in Schedule IV:

941 (1) Any material, compound, mixture, or preparation  
942 containing any of the following narcotic drugs or their  
943 salts calculated as the free anhydrous base or alkaloid, in  
944 limited quantities as set forth below:

945 (a) Not more than one milligram of difenoxin and not  
946 less than twenty-five micrograms of atropine sulfate per  
947 dosage unit;

948 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-  
949 diphenyl-3-methyl-2-propionoxybutane);

950 (c) 2-[(dimethylamino)methyl]-1-(3-  
951 methoxyphenyl)cyclohexanol, its salts, optical and geometric  
952 isomers, and salts of these isomers (including tramadol);

953 (d) Any of the following limited quantities of  
954 narcotic drugs or their salts, which shall include one or  
955 more nonnarcotic active medicinal ingredients in sufficient  
956 proportion to confer upon the compound, mixture or  
957 preparation valuable medicinal qualities other than those  
958 possessed by the narcotic drug alone:

959 a. Not more than two hundred milligrams of codeine per  
960 one hundred milliliters or per one hundred grams;

961           b. Not more than one hundred milligrams of  
962 dihydrocodeine per one hundred milliliters or per one  
963 hundred grams;

964           c. Not more than one hundred milligrams of  
965 ethylmorphine per one hundred milliliters or per one hundred  
966 grams;

967           (2) Any material, compound, mixture or preparation  
968 containing any quantity of the following substances,  
969 including their salts, isomers, and salts of isomers  
970 whenever the existence of those salts, isomers, and salts of  
971 isomers is possible within the specific chemical designation:

972           (a) Alfaxalone;

973           (b) Alprazolam;

974           (c) Barbital;

975           (d) Bromazepam;

976           (e) Camazepam;

977           (f) Carisoprodol;

978           (g) Chloral betaine;

979           (h) Chloral hydrate;

980           (i) Chlordiazepoxide;

981           (j) Clobazam;

982           (k) Clonazepam;

983           (l) Clorazepate;

984           (m) Clotiazepam;

985           (n) Cloxazolam;

986           (o) Delorazepam;

987           (p) Diazepam;

988           (q) Dichloralphenazone;

989           (r) Estazolam;

990           (s) Ethchlorvynol;

991           (t) Ethinamate;

992           (u) Ethyl loflazepate;

993           (v) Fludiazepam;

994 (w) Flunitrazepam;  
995 (x) Flurazepam;  
996 (y) Fospropofol;  
997 (z) Halazepam;  
998 (aa) Haloxazolam;  
999 (bb) Ketazolam;  
1000 (cc) Loprazolam;  
1001 (dd) Lorazepam;  
1002 (ee) Lormetazepam;  
1003 (ff) Mebutamate;  
1004 (gg) Medazepam;  
1005 (hh) Meprobamate;  
1006 (ii) Methohexital;  
1007 (jj) Methylphenobarbital (mephobarbital);  
1008 (kk) Midazolam;  
1009 (ll) Nimetazepam;  
1010 (mm) Nitrazepam;  
1011 (nn) Nordiazepam;  
1012 (oo) Oxazepam;  
1013 (pp) Oxazolam;  
1014 (qq) Paraldehyde;  
1015 (rr) Petrichloral;  
1016 (ss) Phenobarbital;  
1017 (tt) Pinazepam;  
1018 (uu) Prazepam;  
1019 (vv) Quazepam;  
1020 (ww) Suvorexant;  
1021 (xx) Temazepam;  
1022 (yy) Tetrazepam;  
1023 (zz) Triazolam;  
1024 (aaa) Zaleplon;  
1025 (bbb) Zolpidem;  
1026 (ccc) Zopiclone;

1027 (3) Any material, compound, mixture, or preparation  
1028 which contains any quantity of the following substance  
1029 including its salts, isomers and salts of isomers whenever  
1030 the existence of such salts, isomers and salts of isomers is  
1031 possible: fenfluramine;

1032 (4) Any material, compound, mixture, or preparation  
1033 which contains any quantity of the following substances,  
1034 including its salts, isomers, and salts of isomers, whenever  
1035 the existence of such salts, isomers, and salts of isomers  
1036 is possible: Lorcaserin;

1037 (5) Any material, compound, mixture or preparation  
1038 containing any quantity of the following substances having a  
1039 stimulant effect on the central nervous system, including  
1040 their salts, isomers and salts of isomers:

1041 (a) Cathine ((+)-norpseudoephedrine);

1042 (b) Diethylpropion;

1043 (c) Fencamfamin;

1044 (d) Fenproporex;

1045 (e) Mazindol;

1046 (f) Mefenorex;

1047 (g) Modafinil;

1048 (h) Pemoline, including organometallic complexes and  
1049 chelates thereof;

1050 (i) Phentermine;

1051 (j) Pipradrol;

1052 (k) Sibutramine;

1053 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

1054 (6) Any material, compound, mixture or preparation  
1055 containing any quantity of the following substance,  
1056 including its salts:

1057 (a) Butorphanol (including its optical isomers);

1058 (b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-  
1059 2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1 H-

1060 imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid)  
1061 (including its optical isomers) and its salts, isomers, and  
1062 salts of isomers;

1063 (c) Pentazocine;

1064 (7) Ephedrine, its salts, optical isomers and salts of  
1065 optical isomers, when the substance is the only active  
1066 medicinal ingredient;

1067 (8) The department of health and senior services may  
1068 except by rule any compound, mixture, or preparation  
1069 containing any depressant substance listed in subdivision  
1070 (1) of this subsection from the application of all or any  
1071 part of sections 195.010 to 195.320 and sections 579.015 to  
1072 579.086 if the compound, mixture, or preparation contains  
1073 one or more active medicinal ingredients not having a  
1074 depressant effect on the central nervous system, and if the  
1075 admixtures are included therein in combinations, quantity,  
1076 proportion, or concentration that vitiate the potential for  
1077 abuse of the substances which have a depressant effect on  
1078 the central nervous system.

1079 9. The department of health and senior services shall  
1080 place a substance in Schedule V if it finds that:

1081 (1) The substance has low potential for abuse relative  
1082 to the controlled substances listed in Schedule IV;

1083 (2) The substance has currently accepted medical use  
1084 in treatment in the United States; and

1085 (3) The substance has limited physical dependence or  
1086 psychological dependence liability relative to the  
1087 controlled substances listed in Schedule IV.

1088 10. The controlled substances listed in this  
1089 subsection are included in Schedule V:

1090 (1) Any compound, mixture or preparation containing  
1091 any of the following narcotic drugs or their salts  
1092 calculated as the free anhydrous base or alkaloid, in

1093 limited quantities as set forth below, which also contains  
1094 one or more nonnarcotic active medicinal ingredients in  
1095 sufficient proportion to confer upon the compound, mixture  
1096 or preparation valuable medicinal qualities other than those  
1097 possessed by the narcotic drug alone:

1098 (a) Not more than two and five-tenths milligrams of  
1099 diphenoxylate and not less than twenty-five micrograms of  
1100 atropine sulfate per dosage unit;

1101 (b) Not more than one hundred milligrams of opium per  
1102 one hundred milliliters or per one hundred grams;

1103 (c) Not more than five-tenths milligram of difenoxin  
1104 and not less than twenty-five micrograms of atropine sulfate  
1105 per dosage unit;

1106 (2) Any material, compound, mixture or preparation  
1107 which contains any quantity of the following substance  
1108 having a stimulant effect on the central nervous system  
1109 including its salts, isomers and salts of isomers:  
1110 pyrovalerone;

1111 (3) Any compound, mixture, or preparation containing  
1112 any detectable quantity of pseudoephedrine or its salts or  
1113 optical isomers, or salts of optical isomers or any  
1114 compound, mixture, or preparation containing any detectable  
1115 quantity of ephedrine or its salts or optical isomers, or  
1116 salts of optical isomers;

1117 (4) Unless specifically exempted or excluded or unless  
1118 listed in another schedule, any material, compound, mixture,  
1119 or preparation which contains any quantity of the following  
1120 substances having a depressant effect on the central nervous  
1121 system, including its salts:

1122 (a) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-  
1123 propylpyrrolidin-1-yl]butanamide) (also referred to as BRV;  
1124 UCB-34714; Briviact);

1125 (b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-  
1126 phenyl]-carbamic acid ethyl ester];  
1127 (c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-  
1128 propionamide];  
1129 (d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic  
1130 acid];  
1131 (5) Any drug product in finished dosage formulation  
1132 that has been approved by the U.S. Food and Drug  
1133 Administration that contains cannabidiol (2-[1R-3-methyl-6R-  
1134 (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-  
1135 benzenediol) derived from cannabis and no more than 0.1  
1136 percent (w/w) residual tetrahydro cannabinoids.  
1137 11. If any compound, mixture, or preparation as  
1138 specified in subdivision (3) of subsection 10 of this  
1139 section is dispensed, sold, or distributed in a pharmacy  
1140 without a prescription:  
1141 (1) All packages of any compound, mixture, or  
1142 preparation containing any detectable quantity of  
1143 pseudoephedrine, its salts or optical isomers, or salts of  
1144 optical isomers or ephedrine, its salts or optical isomers,  
1145 or salts of optical isomers, shall be offered for sale only  
1146 from behind a pharmacy counter where the public is not  
1147 permitted, and only by a registered pharmacist or registered  
1148 pharmacy technician; and  
1149 (2) Any person purchasing, receiving or otherwise  
1150 acquiring any compound, mixture, or preparation containing  
1151 any detectable quantity of pseudoephedrine, its salts or  
1152 optical isomers, or salts of optical isomers or ephedrine,  
1153 its salts or optical isomers, or salts of optical isomers  
1154 shall be at least eighteen years of age; and  
1155 (3) The pharmacist, intern pharmacist, or registered  
1156 pharmacy technician shall require any person, prior to such  
1157 person's purchasing, receiving or otherwise acquiring such

1158 compound, mixture, or preparation to furnish suitable photo  
1159 identification that is issued by a state or the federal  
1160 government or a document that, with respect to  
1161 identification, is considered acceptable and showing the  
1162 date of birth of the person;

1163 (4) The seller shall deliver the product directly into  
1164 the custody of the purchaser.

1165 12. Pharmacists, intern pharmacists, and registered  
1166 pharmacy technicians shall implement and maintain an  
1167 electronic log of each transaction. Such log shall include  
1168 the following information:

1169 (1) The name, address, and signature of the purchaser;

1170 (2) The amount of the compound, mixture, or  
1171 preparation purchased;

1172 (3) The date and time of each purchase; and

1173 (4) The name or initials of the pharmacist, intern  
1174 pharmacist, or registered pharmacy technician who dispensed  
1175 the compound, mixture, or preparation to the purchaser.

1176 13. Each pharmacy shall submit information regarding  
1177 sales of any compound, mixture, or preparation as specified  
1178 in subdivision (3) of subsection 10 of this section in  
1179 accordance with transmission methods and frequency  
1180 established by the department by regulation;

1181 14. No person shall dispense, sell, purchase, receive,  
1182 or otherwise acquire quantities greater than those specified  
1183 in this chapter.

1184 15. All persons who dispense or offer for sale  
1185 pseudoephedrine and ephedrine products in a pharmacy shall  
1186 ensure that all such products are located only behind a  
1187 pharmacy counter where the public is not permitted.

1188 16. The penalties for a knowing or reckless violation  
1189 of the provisions of subsections 11 to 15 of this section  
1190 are found in section 579.060.

1191           17. The scheduling of substances specified in  
1192 subdivision (3) of subsection 10 of this section and  
1193 subsections 11, 12, 14, and 15 of this section shall not  
1194 apply to any compounds, mixtures, or preparations that are  
1195 in liquid or liquid-filled gel capsule form or to any  
1196 compound, mixture, or preparation specified in subdivision  
1197 (3) of subsection 10 of this section which must be  
1198 dispensed, sold, or distributed in a pharmacy pursuant to a  
1199 prescription.

1200           18. The manufacturer of a drug product or another  
1201 interested party may apply with the department of health and  
1202 senior services for an exemption from this section. The  
1203 department of health and senior services may grant an  
1204 exemption by rule from this section if the department finds  
1205 the drug product is not used in the illegal manufacture of  
1206 methamphetamine or other controlled or dangerous  
1207 substances. The department of health and senior services  
1208 shall rely on reports from law enforcement and law  
1209 enforcement evidentiary laboratories in determining if the  
1210 proposed product can be used to manufacture illicit  
1211 controlled substances.

1212           19. The department of health and senior services shall  
1213 revise and republish the schedules annually.

1214           20. The department of health and senior services shall  
1215 promulgate rules under chapter 536 regarding the security  
1216 and storage of Schedule V controlled substances, as  
1217 described in subdivision (3) of subsection 10 of this  
1218 section, for distributors as registered by the department of  
1219 health and senior services.

1220           21. Logs of transactions required to be kept and  
1221 maintained by this section and section 195.417 shall create  
1222 a rebuttable presumption that the person whose name appears

1223 in the logs is the person whose transactions are recorded in  
1224 the logs.

196.1170. 1. As used in this section, the following  
2 terms mean:

3 (1) "Adulterated", the addition of fentanyl or any  
4 other controlled substance, a synthesized alkaloid or semi-  
5 synthesized alkaloid, or another substance prohibited by law;

6 (2) "Alkaloid fraction", a portion of a plant or plant  
7 extract that contains primarily alkaloid compounds;

8 (3) "Controlled substance", the same meaning as in  
9 section 195.010;

10 (4) "Kratom leaf", the leaf of the *Mitragyna speciosa*  
11 plant in fresh, dehydrated, or dried form;

12 (5) "Kratom leaf extract", the material extracted from  
13 a kratom leaf through the application of a solvent  
14 consisting of water, ethanol, food-grade carbon dioxide, or  
15 another solvent allowed by federal or state law to be used  
16 in the manufacturing of a food ingredient;

17 (6) "Kratom product", a food or dietary supplement  
18 that consists of, or contains, any part of a kratom leaf, a  
19 kratom leaf extract, or any kratom alkaloid, kratom  
20 constituent, or kratom metabolite. "Kratom product" shall  
21 not include any synthesized alkaloids or semi-synthesized  
22 alkaloids;

23 (7) "Semi-synthesized alkaloid", an alkaloid or  
24 alkaloid derivative of the kratom leaf that has been created  
25 by chemical synthesis or biosynthetic means, including, but  
26 not limited to, fermentation, recombinant techniques, yeast-  
27 derived techniques, and enzymatic techniques, rather than by  
28 traditional food preparation techniques such as heat or  
29 extracting.

30 2. No person shall:

31 (1) Knowingly prepare, distribute, advertise, sell, or  
32 offer to sell a kratom product:

33 (a) That is adulterated;

34 (b) To a person under twenty-one years of age;

35 (c) That contains 7-hydroxymitragynine concentrated at  
36 a level above one thousand parts per million on a dry-weight  
37 basis;

38 (d) That is a confection; mimics a candy product; or  
39 is manufactured, packaged, or distributed in a way that is  
40 appealing to children, including, but not limited to, the  
41 distinct shape of a human, an animal, or fruit; or

42 (e) That is combustible or intended for vaporization;

43 (2) Prepare, distribute, advertise, sell, or offer to  
44 sell a kratom product that does not have a label that  
45 clearly and conspicuously sets forth on each retail package:

46 (a) The name and address for the place of business of  
47 the manufacturer or distributor of the kratom product;

48 (b) The full list of ingredients in the kratom product;

49 (c) A disclosure and advice:

50 a. Against use by individuals who are under twenty-  
51 one years of age, pregnant, or breast-feeding;

52 b. To consult a health care professional prior to use;

53 c. That kratom may be habit-forming; and

54 d. That kratom may interact with certain medications,  
55 drugs, and controlled substances;

56 (d) The following statements:

57 a. "THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE  
58 FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED  
59 TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE."; and

60 b. "KEEP OUT OF REACH OF CHILDREN."; and

61 (e) Directions for use that include:

62 a. A recommended amount of the kratom product per  
63 serving;

64 b. The number of recommended servings per package;  
65 c. A recommended number of servings of the kratom  
66 product that can be safely consumed in a twenty-four-hour  
67 period; and  
68 d. Quantitative declarations of the amount of  
69 mitragynine and the amount of 7-hydroxymitragynine per  
70 serving of the kratom product; and  
71 (3) Manufacture, package, label, or distribute a  
72 kratom product that:  
73 (a) Contains synthesized alkaloids or semi-synthesized  
74 alkaloids; or  
75 (b) Has 7-hydroxymitragynine concentrated at a level  
76 above one thousand parts per million on a dry-weight basis.  
77 3. A person that conducts the activities described in  
78 subsection 2 of this section shall be deemed to have engaged  
79 in an unlawful practice in violation of section 407.020.  
196.1175. 1. (1) A person shall not give, sell,  
2 distribute, dispense, or offer for sale a kratom product to  
3 any person who is under twenty-one years of age. Before  
4 giving, selling, distributing, dispensing, or offering to  
5 sell an individual any kratom product, a person shall  
6 request from the individual and examine a government-issued  
7 photographic identification that establishes that the  
8 individual is twenty-one years of age or older. A violation  
9 of this subsection shall constitute an infraction.  
10 (2) It shall be an affirmative defense for any person  
11 alleged to have violated the provisions of subsection 1 of  
12 this section that the person furnishing the kratom product  
13 was presented with and reasonably relied upon a government-  
14 issued photographic identification that identified the  
15 individual receiving the kratom product as being twenty-one  
16 years of age or older.

17           2. Nothing in the provisions of this section shall be  
18 interpreted to prohibit a political subdivision from  
19 enacting an ordinance, rule, or regulation prohibiting the  
20 sale of kratom products to persons under twenty-one years of  
21 age or imposing requirements more stringent than those  
22 provided in this section; provided, that such ordinance,  
23 rule, or regulation does not establish a minimum age to  
24 purchase kratom products that is under twenty-one years of  
25 age.

26           3. As used in this section, the term "kratom" shall  
27 mean:

28           (1) Any part of the leaf of the *Mitragyna speciosa*  
29 plant if the plant contains the alkaloid mitragynine or 7-  
30 hydroxymitragynine; or

31           (2) A synthetic material that contains the alkaloid  
32 mitragynine or 7-hydroxymitragynine.